Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

lined following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and InterMune's revenue is expected to continue to decline; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Each other trademark, trade name or service mark appearing in this news release belongs to its holder.

Financial tables follow


'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: ... and commercializing innovative therapies addressing major unmet medical ... received the Notice of Allowance from the United ... self-delivering RNAi compounds (sd-rxRNA®), for the treatment of ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... LUMBY, BC, Sept. 1 /PRNewswire-FirstCall/ - avVaa World Health ... company, manufacturer and distributor of nationally branded therapeutic, natural ... successfully completed its first week of DRTV 120/60 second ... President and COO of avVaa World Health Care Products ...
... Delaware, September 1 According to a new,market research ... http://www.marketsandmarkets.com ), the,global autoimmune treatment market is expected ... CAGR of 12.7% from 2009 to 2014. The North,American ... the total revenues. , Browse ...
... ... + Phillips, Media Investment Bankers, has announced that James R. Brennan, ... IncumediX and COO/CSO at MediServe Information Systems, Jim currently runs a ... acquisitions, technology license and partnership deals, notably the sale of VanSlyck ...
Cached Biology Technology:avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 2MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 3MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014 4DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 2DeSilva + Phillips, Mediabankers, names Jim Brennan to Head Healthcare IT M&A Practice 3
(Date:4/22/2014)... of breeding bird surveys sent in by citizen scientists ... years, wildlife researchers report that most of the 40 ... higher elevation in response to climate change, but did ... previous studies of potential climate change impacts on wildlife ... have likely underestimated the effects of environmental warming, say ...
(Date:4/22/2014)... is available in French . ... month, sequencing of the complete genome and subsequent phylogenetic ... a clade (variant) that is distinct from strains previously ... Gabon. Epidemiological investigations also linked the laboratory confirmed cases ... outbreak. , Ebola virus is a lethal, highly contagious ...
(Date:4/22/2014)... demonstrate how communities can protect themselves from worsening ... in New England and the Midwest providing practical ... "Our goal is to help communities begin the ... Stack, of Syntectic International, Portland, OR. "It,s important ... move beyond feeling paralyzed from the lack of ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Minnesota projects offer hope and practical help to communities facing more extreme storms 2
... of the journal Cell Metabolism, published by Cell Press, ... glands of mammals meet the incredible metabolic demands of ... undoubtedly affect breast cancer, the findings may have therapeutic ... one of three “isoforms?of the gene known as Akt ...
... of biologists at New York University's Center for Comparative Functional ... The gene plays a part in ensuring that chromosomes are ... nuclear envelope function. The findings appear in the journal Current ... is using functional genomic tools to study the nematode worm ...
... war against flu, researchers at the University of Wisconsin-Madison ... confers broad protection against influenza viruses, including deadly avian ... (Oct. 4, 2006) in the Journal of Virology, describes ... molecule -- that effectively blocks the influenza virus from ...
Cached Biology News:How mammals fuel milk production may have implications for cancer 2How mammals fuel milk production may have implications for cancer 3NYU biologists identify gene that coordinates two cellular processes 2New drug blocks influenza, including bird flu virus 2New drug blocks influenza, including bird flu virus 3
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
...
... A direct, simple approach ... the well surface of an ... anhydride maintains its integrity and ... under dry, room temperature conditions ...
... reagent; Ideal for clarifying many items ... nucleic acids, & proteoglycans; Contains no ... downstream processing; Utilizes a reagent that ... as a suspension in saline; Simple ...
Biology Products: